Glasgow: A new daily pill has shown remarkable potential to reduce bad cholesterol and heart attack risk within 12 weeks.
The international BROADWAY trial, presented at the European Atherosclerosis Society Congress in Glasgow and published in the New England Journal of Medicine, tested Obicetrapib, an oral medication developed for patients with high cardiovascular risk.
Led by Monash University’s Victorian Heart Institute and supported by NewAmsterdam Pharma, the study included over 2,500 patients with existing heart disease or genetic high cholesterol. Participants were given Obicetrapib alongside standard treatments, and results showed a 32.6% drop in LDL cholesterol and a 33.5% drop in lipoprotein(a), a difficult-to-treat inherited risk factor.
According to Professor Stephen Nicholls, who led the trial, Obicetrapib could become a game-changer for patients struggling to meet cholesterol targets despite current therapies. The pill was also well tolerated, with no significant safety concerns reported.
This breakthrough may soon offer new hope to those facing ongoing cardiovascular risks where conventional drugs fall short.
